Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
Identifieur interne : 002B74 ( Ncbi/Checkpoint ); précédent : 002B73; suivant : 002B75Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
Auteurs : Bonnie P. Hersh [États-Unis] ; Nancy L. Earl ; Robert A. Hauser ; Mark StacySource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2010.
English descriptors
- KwdEn :
- Aged, Delayed-Action Preparations, Dopamine Agonists (therapeutic use), Double-Blind Method, Female, Humans, Indoles (therapeutic use), Male, Movement Disorders (diagnosis), Movement Disorders (epidemiology), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , therapeutic use : Dopamine Agonists, Indoles.
- chemical : Delayed-Action Preparations.
- diagnosis : Movement Disorders.
- drug therapy : Parkinson Disease.
- epidemiology : Movement Disorders, Parkinson Disease.
- Aged, Double-Blind Method, Female, Humans, Male, Severity of Illness Index, Treatment Outcome.
Abstract
We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.
DOI: 10.1002/mds.23040
PubMed: 20461810
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001828
- to stream PubMed, to step Curation: 001828
- to stream PubMed, to step Checkpoint: 001917
- to stream Ncbi, to step Merge: 002B74
- to stream Ncbi, to step Curation: 002B74
Links to Exploration step
pubmed:20461810Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.</title><author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P" last="Hersh">Bonnie P. Hersh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215, USA. bonnie_hersh@vmed.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215</wicri:regionArea><wicri:noRegion>Massachusetts 02215</wicri:noRegion></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L" last="Earl">Nancy L. Earl</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.23040</idno><idno type="RBID">pubmed:20461810</idno><idno type="pmid">20461810</idno><idno type="wicri:Area/PubMed/Corpus">001828</idno><idno type="wicri:Area/PubMed/Curation">001828</idno><idno type="wicri:Area/PubMed/Checkpoint">001917</idno><idno type="wicri:Area/Ncbi/Merge">002B74</idno><idno type="wicri:Area/Ncbi/Curation">002B74</idno><idno type="wicri:Area/Ncbi/Checkpoint">002B74</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.</title><author><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P" last="Hersh">Bonnie P. Hersh</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215, USA. bonnie_hersh@vmed.org</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Harvard Vanguard Medical Associates, Boston, Massachusetts 02215</wicri:regionArea><wicri:noRegion>Massachusetts 02215</wicri:noRegion></affiliation></author><author><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L" last="Earl">Nancy L. Earl</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Delayed-Action Preparations</term><term>Dopamine Agonists (therapeutic use)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Indoles (therapeutic use)</term><term>Male</term><term>Movement Disorders (diagnosis)</term><term>Movement Disorders (epidemiology)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Delayed-Action Preparations</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Movement Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Movement Disorders</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We performed a retrospective analysis of the Efficacy And Safety Evaluation in Parkinson's Disease (EASE-PD) Adjunct Study, assessing the minimum time to symptom improvement after initiation of ropinirole prolonged release (2-24 mg/day) versus placebo in patients with moderate-to-advanced PD not optimally controlled with levodopa. Ropinirole prolonged release was superior to placebo at Week 2 for change from baseline in "off" time (adjusted mean treatment difference [AMTD] - 0.7 hours; 95% confidence interval [CI], -1.1, -0.2; P = 0.0029), and "on" time without troublesome dyskinesia (0.4 hours; 95%CI, 0.01, 0.88; P = 0.0444). At Week 4, improvements were seen in change from baseline in Unified Parkinson's Disease Rating Scale total motor score (AMTD, -3.1; 95%CI, -4.4, -1.8; P < 0.0001), activities of daily living score (AMTD, -1.1; 95%CI, -1.7, -0.5; P = 0.0004), and the cardinal symptoms of PD compared with placebo. These analyses indicate that once-daily, adjunctive ropinirole prolonged release can offer PD symptom control 2 weeks after treatment initiation.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Earl, Nancy L" sort="Earl, Nancy L" uniqKey="Earl N" first="Nancy L" last="Earl">Nancy L. Earl</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A" last="Hauser">Robert A. Hauser</name><name sortKey="Stacy, Mark" sort="Stacy, Mark" uniqKey="Stacy M" first="Mark" last="Stacy">Mark Stacy</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Hersh, Bonnie P" sort="Hersh, Bonnie P" uniqKey="Hersh B" first="Bonnie P" last="Hersh">Bonnie P. Hersh</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002B74 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 002B74 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:20461810
|texte= Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:20461810" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |